![IJERPH | Free Full-Text | School-Based Interventions to Support Healthy Indoor and Outdoor Environments for Children: A Systematic Review IJERPH | Free Full-Text | School-Based Interventions to Support Healthy Indoor and Outdoor Environments for Children: A Systematic Review](https://pub.mdpi-res.com/ijerph/ijerph-20-01746/article_deploy/html/images/ijerph-20-01746-g001-550.jpg?1674991376)
IJERPH | Free Full-Text | School-Based Interventions to Support Healthy Indoor and Outdoor Environments for Children: A Systematic Review
![Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer: Molecular Therapy - Nucleic Acids Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/asset/e8d4000d-86f3-44df-98ed-d887b47d0e31/fx1.jpg)
Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer: Molecular Therapy - Nucleic Acids
Selection of DNA Aptamers against Epithelial Cell Adhesion Molecule for Cancer Cell Imaging and Circulating Tumor Cell Capture | Analytical Chemistry
Glioblastoma: Current Status, Emerging Targets, and Recent Advances | Journal of Medicinal Chemistry
![Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity - ScienceDirect Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610821003391-fx1.jpg)
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity - ScienceDirect
![DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival | Nature Communications DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-33215-x/MediaObjects/41467_2022_33215_Fig1_HTML.png)
DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival | Nature Communications
![IJMS | Free Full-Text | Current Molecular Combination Therapies Used for the Treatment of Breast Cancer IJMS | Free Full-Text | Current Molecular Combination Therapies Used for the Treatment of Breast Cancer](https://pub.mdpi-res.com/ijms/ijms-23-11046/article_deploy/html/images/ijms-23-11046-g001.png?1663830620)
IJMS | Free Full-Text | Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
![The Obstacle Is the Way: The Timeless Art of Turning Trials into Triumph: Holiday, Ryan: 8601411257797: Amazon.com: Books The Obstacle Is the Way: The Timeless Art of Turning Trials into Triumph: Holiday, Ryan: 8601411257797: Amazon.com: Books](https://m.media-amazon.com/images/I/71Za+yDrvTL._AC_UF1000,1000_QL80_.jpg)
The Obstacle Is the Way: The Timeless Art of Turning Trials into Triumph: Holiday, Ryan: 8601411257797: Amazon.com: Books
Efficient Polymer-Mediated Delivery of Gene-Editing Ribonucleoprotein Payloads through Combinatorial Design, Parallelized Experimentation, and Machine Learning | ACS Nano
![The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination | Science Translational Medicine The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination | Science Translational Medicine](https://www.science.org/cms/asset/b386e6a4-4655-41f2-86eb-c9d8cd426f1c/keyimage.gif)
The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination | Science Translational Medicine
![Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/cdd06698-d083-4bf7-bdfe-88d56ffeef11/gr1.jpg)
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine
![Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial - The Lancet Oncology Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/7ed46082-53dd-41f8-b4f2-3fdb0685d456/gr1.jpg)